-
1por Jagannath, Sundar, Lin, Yi, Goldschmidt, Hartmut, Reece, Donna, Nooka, Ajay, Senin, Alicia, Rodriguez-Otero, Paula, Powles, Ray, Matsue, Kosei, Shah, Nina, Anderson, Larry D., Streetly, Matthew, Wilson, Kimberly, Le, Hoa Van, Swern, Arlene S., Agarwal, Amit, Siegel, David S.“…Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, demonstrated efficacy in triple-class exposed RRMM patients in the KarMMa trial (NCT03361748). In this retrospective study (KarMMa-RW), patient-level data from triple-class exposed RRMM patients were merged into a single data model and compared with KarMMa using trimmed stabilized inverse probability of treatment weighting. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2por McGarvey, November, Ung, Brian, Carattini, Thomas, Imanak, Ken, Lee, Abraham, Campbell, Timothy B., Patwardhan, Pallavi“…Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell therapy, showed deep, durable responses in patients with RRMM in the pivotal phase 2 KarMMa trial (NCT03361748). Healthcare resource utilization (HCRU) and costs were estimated for ide-cel-treated patients in the KarMMa trial. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3por Alsina, Melissa, Dhodapkar, Madhav, Berdeja, Jesus, Patel, Krina, Richard, Shambavi, Vij, Ravi, Leleu, Xavier, Egan, Daniel, Leif Bergsagel, P., Ran, Reshef, Usmani, Saad Z, Truppel-Hartmann, Anna, Basudhar, Debashree, Thompson, Ethan, Zheng, Xirong, Zhong, Xiaobo, Greggio, Chiara, Popa Mckiver, Mihaela, Carrasco Alfonso, Marlene, Siegel, DavidEnlace del recurso
Publicado 2023
Enlace del recurso
Online Artículo Texto -
4por Rodríguez-Otero, P, San-Miguel, J, Anderson, LD, Lonial, S, Truppel-Hartmann, A, Sanford, J, Rowe, E, Campbell, TB, Munshi, NEnlace del recurso
Publicado 2022
Enlace del recurso
Online Artículo Texto -
5por Rodríguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A.K., Manier, S., Callander, N., Costa, L.J., Vij, R., Bahlis, N.J., Moreau, P., Solomon, S.R., Delforge, M., Berdeja, J., Truppel-Hartmann, A., Yang, Z., Favre-Kontula, L., Wu, F., Piasecki, J., Cook, M., Giralt, S.Enlace del recurso
Publicado 2023
Enlace del recurso
Online Artículo Texto -
6por Piasecki, Julia, Desai, Keyur, Courtney, Carolyn, Thompson, Ethan, Pratt, James, Raje, Noopur, Patel, Krina, Raab, Marc S., Cook, Mark, Simonsen, Katy, Popa Mckiver, Mihaela, Kaiser, Shari, Martin, NathanEnlace del recurso
Publicado 2023
Enlace del recurso
Online Artículo Texto -
7por Patel, Krina, Rodríguez-Otero, Paula, Manier, Salomon, Baz, Rachid, Raab, Marc S., Cavo, Michele, Callander, Natalie, Costa, Luciano, Moreau, Philippe, Solomon, Scott, Chen, Christine, Raje, Noopur, Scheid, Christof, Delforge, Michel, Larsen, Jeremy, Pabst, Thomas, Suzuki, Kenshi, Truppel-Hartmann, Anna, Yang, Zhihong, Piasecki, Julia, Felten, Jasper, Caia, Andrea, Cook, Mark, Giralt, Sergio, Mateos, Maria-VictoriaEnlace del recurso
Publicado 2023
Enlace del recurso
Online Artículo Texto -
8por Martin, N., Xu, A., Stong, N., Rytlewski, J., Finney, O., Campbell, T., Pierceall, W., Flynt, E., Thompson, E., Kaiser, S.Enlace del recurso
Publicado 2022
Enlace del recurso
Online Artículo Texto -
9por Manier, Salomon, Rodríguez-Otero, Paula, Mateos, Maria-Victoria, Einsele, Hermann, Bahlis, Nizar J, Munshi, Nikhil, Ailawadhi, Sikander, Arnulf, Bertrand, Nooka, Ajay, Vij, Ravi, Weum Abrahamsen, Ingerid, Broijl, Annemiek, Jagannath, Sundar, Benjamin, Reuben, Gergis, Usama, Sborov, Douglas W., Iida, Shinsuke, Truppel-Hartmann, Anna, Yang, Zhihong, Piasecki, Julia, Felten, Jasper, Caia, Andrea, Cook, Mark, Baz, RachidEnlace del recurso
Publicado 2023
Enlace del recurso
Online Artículo Texto -
10por Rodríguez-Otero, P, Shah, N, Munshi, N, Berdeja, J, Jagannath, S, Finney, O, Martin, N, Agarwal, A, Rowe, E, Campbell, T, San-Miguel, JEnlace del recurso
Publicado 2022
Enlace del recurso
Online Artículo Texto -
11por Delforge, Michel, Patel, Krina, Eliason, Laurie, Dhanda, Devender, Shi, Ling, Guo, Shien, Marshall, Thomas, Arnulf, Bertrand, Cavo, Michele, Nooka, Ajay, Manier, Salomon, Callander, Natalie, Giralt, Sergio, Einsele, Hermann, Ailawadhi, Sikander, Popa Mckiver, Mihaela, Cook, Mark, Rodríguez-Otero, PaulaEnlace del recurso
Publicado 2023
Enlace del recurso
Online Artículo Texto -
12por Ayers, Dieter, Cope, Shannon, Towle, Kevin, Mojebi, Ali, Marshall, Thomas, Dhanda, Devender“…These distributions were incorporated into survival models, which constrained the expected survival based on standard survival distributions informed by IPD from KarMMa. RESULTS: Models for ide-cel that combined KarMMa data with expert opinion were more consistent in terms of survival as well as mean survival at 10 years (survival point estimates under different parametric models were 29–33% at 3 years, 5–17% at 5 years, and 0–6% at 10 years) versus models with KarMMa data alone (11–39% at 3 years, 0–25% at 5 years, and 0–11% at 10 years). …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
13por Minakata, Daisuke, Ishida, Tadao, Ando, Kiyoshi, Suzuki, Rikio, Tanaka, Junji, Hagiwara, Shotaro, Ananthakrishnan, Revathi, Kuwayama, Shigeki, Nishio, Mitsufumi, Kanda, Yoshinobu, Suzuki, Kenshi“…BACKGROUND: In the phase 2 KarMMa trial, patients with relapsed/refractory multiple myeloma (RRMM) achieved deep and durable responses with idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T cell therapy. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14por Delforge, Michel, Shah, Nina, Miguel, Jesús San F., Braverman, Julia, Dhanda, Devender S., Shi, Ling, Guo, Shien, Yu, Peiwen, Liao, Weiqin, Campbell, Timothy B., Munshi, Nikhil C.“…Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen–directed chimeric antigen receptor T cell therapy, showed deep, durable responses in patients with triple-class exposed, relapsed and refractory multiple myeloma (RRMM) in the phase 2 KarMMa (Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma) trial. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
15por Connarn, Jamie N., Witjes, Han, van Zutphen‐van Geffen, Marielle, de Greef, Rik, Campbell, Timothy B., Hege, Kristen, Zhou, Simon, Lamba, Manisha“…Ide‐cel exposure data were available from 127 patients treated at target doses of 150, 300, or 450 × 10(6) CAR+ T cells from the phase II KarMMa study (NCT03361748). Key exposure metrics, including area under the curve of the transgene level from 0 to 28 days and maximum transgene level, were calculated using noncompartmental methods. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
16“…Two distinct CAR-based therapeutics designed to target BCMA are now FDA-approved based upon robust, sustained responses in heavily-pretreated multiple myeloma (MM) patients enrolled on the KarMMa and CARTITUDE-1 studies. While promising, CAR T-cells present unique challenges such as antigen escape and T-cell exhaustion. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
17por Logue, Jennifer M., Peres, Lauren C., Hashmi, Hamza, Colin-Leitzinger, Christelle M., Shrewsbury, Alexandria M., Hosoya, Hitomi, Gonzalez, Rebecca M., Copponex, Christina, Kottra, Krista H., Hovanky, Vanna, Sahaf, Bita, Patil, Sunita, Lazaryan, Aleksandr, Jain, Michael D., Baluch, Aliyah, Klinkova, Olga V., Bejanyan, Nelli, Faramand, Rawan G., Elmariah, Hany, Khimani, Farhad, Davila, Marco L., Mishra, Asmita, Blue, Brandon J., Grajales-Cruz, Ariel F., Castaneda Puglianini, Omar A., Liu, Hien D., Nishihori, Taiga, Freeman, Ciara L., Brayer, Jason B., Shain, Kenneth H., Baz, Rachid C., Locke, Frederick L., Alsina, Melissa, Sidana, Surbhi, Hansen, Doris K.“…Idecabtagene vicleucel (ide-cel) was FDA-approved in March 2021 for the treatment of relapsed/refractory multiple myeloma after 4 lines of therapy. On the KarMMa trial, grade ≥ 3 cytopenias and infections were common. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto
